Cargando…

The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy

PURPOSE: This clinical study sought to determine whether the levels of inflammatory markers predicted the survival of advanced gastric cancer (AGC) patients who underwent anti-programmed death 1 (PD-1) therapy. METHODS: Using AGC patient plasma samples and baseline characteristics, we investigated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Ziting, Wang, Qianling, Wang, Hui, Jiao, Yang, Li, Min, Wei, Wei, Lei, Yu, Zhao, Zhiyan, Zhang, Tengteng, Zhang, Yiyin, Gu, Kangsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845037/
https://www.ncbi.nlm.nih.gov/pubmed/35178344
http://dx.doi.org/10.3389/fonc.2022.783197
_version_ 1784651593181822976
author Qu, Ziting
Wang, Qianling
Wang, Hui
Jiao, Yang
Li, Min
Wei, Wei
Lei, Yu
Zhao, Zhiyan
Zhang, Tengteng
Zhang, Yiyin
Gu, Kangsheng
author_facet Qu, Ziting
Wang, Qianling
Wang, Hui
Jiao, Yang
Li, Min
Wei, Wei
Lei, Yu
Zhao, Zhiyan
Zhang, Tengteng
Zhang, Yiyin
Gu, Kangsheng
author_sort Qu, Ziting
collection PubMed
description PURPOSE: This clinical study sought to determine whether the levels of inflammatory markers predicted the survival of advanced gastric cancer (AGC) patients who underwent anti-programmed death 1 (PD-1) therapy. METHODS: Using AGC patient plasma samples and baseline characteristics, we investigated the specific value of inflammatory markers in AGC from a clinical perspective in immunotherapy. RESULTS: One hundred and six patients with AGC who underwent anti-PD-1 therapy were enrolled in this study between 20 July 2019 and 16 March 2021. A significant decrease in NLR, dNLR, and SII was noticed among the PR (P=0.023; P=0.036; P=0.001), SD (P=0.048; P=0.022; P=0.023), ORR (P=0.021; P=0.032; P=0.001), and DCR (P=0.003; P=0.001; P<0.001) groups after anti-PD-1 therapy. Additionally, a significant decline of PLR was also observed in PR (P=0.010), ORR (P=0.007), and DCR (P=0.005) after anti-PD-1 therapy. Only MLR levels increased significantly at the time of anti-PD-1 immunotherapy the failure compared to baseline (P=0.039). And statistically significant elevations in NLR (P=0.001), MLR (P=0.020), dNLR (P=0.002), and SII (P=0.019) were found in failure of anti-PD-1 treatment compared to optimal efficacy in AGC patients. In first-line treatment, the number of metastatic sites (P=0.001) was an independent prognostic factor for PFS, and peritoneal metastases (P=0.004) and platelet-to-lymphocyte ratio (PLR) level (P=0.014) were independent prognostic predictors of OS according to Cox regression analysis. In second-line or posterior treatment, the number of metastatic sites (P=0.007), ECOG (P=0.011), and PLR level (P=0.033) were independent prognostic factors for PFS in AGC patients, and the number of metastatic sites (P=0.003), differentiation (P=0.030), and NLR level (P<0.001) were independent prognostic factors for OS according to Cox regression analysis. CONCLUSIONS: NLR, PLR, MLR, dNLR, and SII can reflect the short-term efficacy of immunotherapy in patients who underwent anti-PD-1 therapy with AGC. PLR is an independent prognostic factor for OS in AGC patients receiving first-line immunotherapy and PFS in those receiving second-line or posterior immunotherapy. And NLR was an independent prognostic factor for OS in AGC patients receiving second-line or posterior immunotherapy. The number of metastatic sites was significantly associated with the prognosis of AGC patients who received immunotherapy.
format Online
Article
Text
id pubmed-8845037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88450372022-02-16 The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy Qu, Ziting Wang, Qianling Wang, Hui Jiao, Yang Li, Min Wei, Wei Lei, Yu Zhao, Zhiyan Zhang, Tengteng Zhang, Yiyin Gu, Kangsheng Front Oncol Oncology PURPOSE: This clinical study sought to determine whether the levels of inflammatory markers predicted the survival of advanced gastric cancer (AGC) patients who underwent anti-programmed death 1 (PD-1) therapy. METHODS: Using AGC patient plasma samples and baseline characteristics, we investigated the specific value of inflammatory markers in AGC from a clinical perspective in immunotherapy. RESULTS: One hundred and six patients with AGC who underwent anti-PD-1 therapy were enrolled in this study between 20 July 2019 and 16 March 2021. A significant decrease in NLR, dNLR, and SII was noticed among the PR (P=0.023; P=0.036; P=0.001), SD (P=0.048; P=0.022; P=0.023), ORR (P=0.021; P=0.032; P=0.001), and DCR (P=0.003; P=0.001; P<0.001) groups after anti-PD-1 therapy. Additionally, a significant decline of PLR was also observed in PR (P=0.010), ORR (P=0.007), and DCR (P=0.005) after anti-PD-1 therapy. Only MLR levels increased significantly at the time of anti-PD-1 immunotherapy the failure compared to baseline (P=0.039). And statistically significant elevations in NLR (P=0.001), MLR (P=0.020), dNLR (P=0.002), and SII (P=0.019) were found in failure of anti-PD-1 treatment compared to optimal efficacy in AGC patients. In first-line treatment, the number of metastatic sites (P=0.001) was an independent prognostic factor for PFS, and peritoneal metastases (P=0.004) and platelet-to-lymphocyte ratio (PLR) level (P=0.014) were independent prognostic predictors of OS according to Cox regression analysis. In second-line or posterior treatment, the number of metastatic sites (P=0.007), ECOG (P=0.011), and PLR level (P=0.033) were independent prognostic factors for PFS in AGC patients, and the number of metastatic sites (P=0.003), differentiation (P=0.030), and NLR level (P<0.001) were independent prognostic factors for OS according to Cox regression analysis. CONCLUSIONS: NLR, PLR, MLR, dNLR, and SII can reflect the short-term efficacy of immunotherapy in patients who underwent anti-PD-1 therapy with AGC. PLR is an independent prognostic factor for OS in AGC patients receiving first-line immunotherapy and PFS in those receiving second-line or posterior immunotherapy. And NLR was an independent prognostic factor for OS in AGC patients receiving second-line or posterior immunotherapy. The number of metastatic sites was significantly associated with the prognosis of AGC patients who received immunotherapy. Frontiers Media S.A. 2022-02-01 /pmc/articles/PMC8845037/ /pubmed/35178344 http://dx.doi.org/10.3389/fonc.2022.783197 Text en Copyright © 2022 Qu, Wang, Wang, Jiao, Li, Wei, Lei, Zhao, Zhang, Zhang and Gu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qu, Ziting
Wang, Qianling
Wang, Hui
Jiao, Yang
Li, Min
Wei, Wei
Lei, Yu
Zhao, Zhiyan
Zhang, Tengteng
Zhang, Yiyin
Gu, Kangsheng
The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy
title The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy
title_full The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy
title_fullStr The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy
title_full_unstemmed The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy
title_short The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy
title_sort effect of inflammatory markers on the survival of advanced gastric cancer patients who underwent anti-programmed death 1 therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845037/
https://www.ncbi.nlm.nih.gov/pubmed/35178344
http://dx.doi.org/10.3389/fonc.2022.783197
work_keys_str_mv AT quziting theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT wangqianling theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT wanghui theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT jiaoyang theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT limin theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT weiwei theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT leiyu theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT zhaozhiyan theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT zhangtengteng theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT zhangyiyin theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT gukangsheng theeffectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT quziting effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT wangqianling effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT wanghui effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT jiaoyang effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT limin effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT weiwei effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT leiyu effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT zhaozhiyan effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT zhangtengteng effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT zhangyiyin effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy
AT gukangsheng effectofinflammatorymarkersonthesurvivalofadvancedgastriccancerpatientswhounderwentantiprogrammeddeath1therapy